Related Experiment Video
Updated: Mar 7, 2026

An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment
Published on: December 3, 2020
Development of a Discriminative In Vitro Release Test for Rivastigmine Transdermal Patches Using Pharmacopeial
Alice Simon1, Maria Inês Amaro2, Anne Marie Healy2
1Department of Drugs and Pharmaceutics, Faculty of Pharmacy, Federal University of Rio de Janeiro, Av. Carlos Chagas Filho, 373, CCS, Bss, Sala 15, Rio de Janeiro, RJ, 21941-902, Brazil.
Abstract:
The aim of this study was to develop and validate a discriminating in vitro release test to evaluate rivastigmine transdermal patches. The Exelon® Patch was chosen as a model transdermal product. The studies of in vitro release were designed to determine the impact of the official apparatus chosen (USP apparatus 5 and USP apparatus 6), the rotation speed, and the dissolution medium characteristics on the rivastigmine release profile from transdermal patches. Patches with different drug release profiles were tested in order to evaluate the discriminating power of the in vitro release test developed and validated. Variables such as the apparatus type, the dissolution medium, and the rotation speed have a significant influence on the drug release characteristics from a transdermal patch. The in vitro release methodologies using the USP apparatus 5 at 50 rpm and USP apparatus 6 at 25 rpm using the medium phosphate-buffered saline pH 7.4 were considered discriminative and adequate to characterize the rivastigmine (RV) release from a commercial transdermal patch, Exelon® Patch.
Related Concept Videos
In Vitro Drug Dissolution: Compendial Testing Models II
In Vitro Drug Release Testing: Overview, Development and Validation
In Vitro Drug Dissolution: Compendial Testing Models I
In Vitro Drug Dissolution: Alternative Methods
Clinically Relevant Drug Product Specifications: Methods of Establishment
Drug Dissolution: Requirements and Profile Comparison

